Refrat Adverse Reactions

The adverse event profile associated with the use of immunosuppressive drugs is often difficult to establish owing to the presence of the underlying diseases and the concurrent use of many other medications.
The most frequently reported adverse effects associated with mycophenolate mofetil therapy are diarrhoea, leukopenia, sepsis, vomiting, higher frequency of infections, including opportunistic infections (e.g., CMV infections, herpes zoster, herpes simplex, candidal infections, aspergillosis, and Pneumocystis carinii pneumonia).
Adverse reactions occurring in 20% or more of patients receiving mycophenolate mofetil include pain (e.g. abdominal, chest, back), fever, headache, anaemia (e.g., hypochromic), thrombocytopenia, leukocytosis, urinary tract infection, abnormal renal function, hypertension, hypotension, cardiovascular disorder, tachycardia, oedema (e.g., peripheral), hypercholesteremia, hypokalemia, hyperkalemia, hyperglycemia, increases in blood urea nitrogen (BUN) and serum creatinine concentration, increased lactic dehydrogenase, hypomagnesemia, hypocalcemia, constipation, dyspepsia, nausea, vomiting, anorexia, abnormal liver function test results, cough, dyspnoea, lung disorder, sinusitis, pleural effusion, rash, tremor, insomnia, dizziness, anxiety, and paresthesia.
Other adverse effects: Gastrointestinal: colitis (sometimes caused by cytomegalovirus), pancreatitis, isolated cases of intestinal villous atrophy.
Disorders of immunosuppression: serious life threatening infections such as meningitis and infectious endocarditis have been reported occasionally; there is evidence of a higher frequency of certain types of infections such as tuberculosis and atypical mycobacterial infection.